Nội dung của trang này:
Nội dung của trang này:
Tổng quan
Chronic myeloid leukemia is a myeloid disorder associated with the
Philadelphia (Ph) chromosome, t(9;22)(q34;q11), resulting in the fusion of the
breakpoint cluster region (BCR) and Abelson murine leukemia (ABL1)
genes. This is stated in the Introduction
section as well are the phases of CML, acute, chronic, and blastic.
Chronic Myeloid Leukemia_Disease SummaryIt is discussed in the Epidemiology section that CML accounts for 15% of all leukemias in adults with a median age of presentation of >50 years old in Western countries, and <50 years old in Asian and African countries. Other details regarding its incidence are also found in this section.
The Pathophysiology section discusses how the fusion oncoprotein, BCR::ABL1, leads to the production of a constitutively active tyrosine kinase. As stated in the Risk Factors section, the only known risk factor for CML is ionizing radiation.
The Classification section discusses in more detail the different phases of CML.
History and Physical Examination
The Clinical Presentation
section states the various signs and symptoms of CML.
As mentioned in the Physical
Examination section, crucial to the diagnosis of CML is doing a
complete history and physical examination that includes the size of the spleen
and liver.
Chẩn đoán
The different diagnostic tests that can be done in CML are
enumerated and discussed in the Laboratory
Tests and Ancillaries.
The Differential Diagnosis
section enumerates the diseases that may mimic CML. These should be ruled out.
Xử trí
Determination of risk scores using different scoring systems
is discussed in the Evaluation
section.
The Principles of Therapy section mentions the
recommendations in treatment, the importance of adherence to tyrosine kinase
inhibitor (TKI) therapy, and the criteria for discontinuation of therapy.
The Pharmacological
Therapy section includes discussions of different cancer
therapies in CML such as targeted cancer therapy, cytotoxic chemotherapy, and
cancer immunotherapy. Also discussed in this section is the management of
toxicities, management of resistance, and supportive care.
The Surgery
section contains details on hematopoietic cell transplant (HCT).
Details on treatment response assessment and follow-up are
found in the Monitoring
section.
